EUVIMEDEUVIMED entdecken
Open Access

Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer

Shouhai Zhu, Huanyao Gao, Dan Jiang, Guijie Guo, Jing Hou, Yiqun Han, Chao Zhang, Xiaoping Hu, Shreya Indulkar, Jake A Kloeber, Qi Hu, Yanxia Jiang und 16 weitere

Molecular Cell · 2025

DOI: 10.1016/j.molcel.2025.06.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Cell, 2025. Verfasst von Shouhai Zhu und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm, DNA Replication, Histone-Lysine N-Methyltransferase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Mayo Foundation for Medical Education and Research, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsDrug Resistance, NeoplasmDNA ReplicationHistone-Lysine N-MethyltransferaseProstatic Neoplasms, Castration-ResistantHumansMaleAnimalsMiceCullin ProteinsProtein IsoformsCell Line, TumorUbiquitinationAtaxia Telangiectasia Mutated ProteinsMRE11 Homologue ProteinXenograft Model Antitumor AssaysProteolysis

Stichwörter der Autor:innen

CUL3MRE11NSD3PARP inhibitorPTIPprostate cancerproteolysis-targeting chimerareplication fork

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsCullin ProteinsHistone-Lysine N-MethyltransferaseProtein IsoformsCUL3 protein, humanAtaxia Telangiectasia Mutated ProteinsATR protein, humanMRE11 Homologue Protein

Autor:innen und Institutionen

  • Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: tu.xinyi@mayo.edu.

Förderung

  • NCI NIH HHS
  • Mayo Foundation for Medical Education and Research
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Zhu, S., Gao, H., Jiang, D., Guo, G., Hou, J., Han, Y., Zhang, C., Hu, X., Indulkar, S., Kloeber, J. A., Hu, Q., Jiang, Y., Zeng, X., Ouyang, Y., Lu, J., Yin, P., Luo, K., Huang, J., Wu, Z., …, & Lou, Z. (2025). Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer. Molecular Cell. https://doi.org/10.1016/j.molcel.2025.06.004

Vancouver

Zhu S, Gao H, Jiang D, Guo G, Hou J, Han Y, et al. Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer. Molecular Cell. 2025. doi:10.1016/j.molcel.2025.06.004

BibTeX
@article{Zhu2025,
  author = {Zhu, Shouhai and Gao, Huanyao and Jiang, Dan and Guo, Guijie and Hou, Jing and Han, Yiqun and Zhang, Chao and Hu, Xiaoping and Indulkar, Shreya and Kloeber, Jake A and Hu, Qi and Jiang, Yanxia and Zeng, Xiangyu and Ouyang, Yaobin and Lu, Jing and Yin, Ping and Luo, Kuntian and Huang, Jinzhou and Wu, Zheming and Chen, Bin and Xiao, Huaping and Dragojevic, Sonja and Qin, Hongran and Zhou, Xiang and Jin, Jian and Tu, Xinyi and Wang, Liewei and Lou, Zhenkun},
  title = {Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer},
  journal = {Molecular Cell},
  year = {2025},
  doi = {10.1016/j.molcel.2025.06.004}
}
Kostenlos starten →